The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors
about
Mechanisms of TGFβ-Induced Epithelial-Mesenchymal TransitionThe role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerMicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancerEmerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung CancerAdvanced Research on MicroRNAs and EGFR-TKIs Secondary ResistanceGene 33/Mig6 inhibits hexavalent chromium-induced DNA damage and cell transformation in human lung epithelial cellsDownregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signalingMolecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.The translational significance of epithelial-mesenchymal transition in head and neck cancer.Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.MicroRNA (miRNA) in cancerLoss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.miR-203 is involved in the laryngeal carcinoma pathogenesis via targeting VEGFA and Cox-2.miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axisPersonalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Epithelial Mesenchymal Transition: a double-edged sword.MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cellsmiR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.MicroRNAs and Cancer Drug Resistance.The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.miRNAs: mediators of ErbB family targeted therapy resistance.Noncoding RNAs in Therapeutic Resistance of Cancer.Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitorInterplay between miRNAs and human diseases.The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting METSuppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Simultaneous Detection of Autophagy and Epithelial to Mesenchymal Transition in the Non-small Cell Lung Cancer Cells.Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.Prospects for new lung cancer treatments that target EMT signaling.The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion.
P2860
Q26745545-AEAE4939-8ACE-498A-96C8-0F59C166BA6AQ26749110-BB0587E6-3153-44B7-9C94-6E53C89A6457Q26777313-A51DF6B0-42AB-4E2E-AD45-B6B442509F5AQ26798147-8D49989A-33EB-4AA4-8DE1-DA651A285F13Q28069990-834B9457-E088-484C-80C2-7BD071FFF68BQ28395858-00785A99-00C1-40E0-A256-4A8A9BF64CFFQ33650801-A43A22C1-FB6A-499F-9DB1-0206CFB353D5Q34177065-3BCA501A-DDCA-4CD4-A01A-0B24CD905883Q34996810-441A8932-36FD-43CB-A9D8-43C6E1B9426FQ35176428-B67C797D-8C5B-4A95-B97E-DB90D0936DB6Q35550226-057B675A-9374-45CD-885A-9DC0F8F3F9CAQ35583538-91A0A370-ABC3-4807-988F-778829DF3894Q36028210-AD74EE8F-7BB6-496A-A01B-9DE26288F460Q36093612-D64C242A-EF16-48E0-A991-979D167D7060Q37077423-DA1A9E6B-C0B8-4F65-861C-584EAE99C379Q37142987-E2876F31-4DA9-42E0-A28D-2C669913A9CFQ37611689-4AE0E157-632C-43AF-9E8B-4EB1F80F6498Q37687142-D2E61B9A-7F8A-413B-8170-33525111A2ACQ38400481-01C55CDC-A0F8-4E30-A98D-4DF18229BDD4Q38453116-5917CF87-2C9C-4B30-8CE8-3689FF170825Q38709287-8ECA6FA4-86D4-4574-B5C3-2F839278A743Q38727344-CFE566F5-758F-4AC1-93E1-DB369C2803BEQ38728165-52D1798C-EAB5-48C7-9F5E-650772C286DCQ38748118-572B1C92-C811-4920-8439-1A1BFA66286DQ38748123-973C60BE-D341-44AE-8998-9513B4EE92E5Q38881549-594747AD-7AFC-42AD-8DF2-954595735077Q38885495-C880C83E-3BBF-4276-939C-722309D0E780Q38954685-EFA57774-F5CA-4714-B566-1A5290B5EE2FQ39127898-7A8756B6-9BB5-4A0C-B5E5-F818CCC67B25Q39148511-E9709F58-4711-4E89-9149-6DA198178DFAQ41134348-DDF31400-DE76-4801-BC1B-7FBEBAD1CA8CQ47671139-0FAAA612-B04B-4FAD-975C-474E06342E91Q47723800-58BA5E1B-5892-460B-AD88-A7F2CAD3093BQ48070194-527BC7CE-2A65-400B-83C1-F78F4E974E53Q48271468-6CCBA7C0-BAF1-4869-895B-312BBB60B9ECQ51185572-23E64D31-CB6F-4A60-9731-BFD4956ADE72Q51734405-EB3FB83D-6BB8-4B13-B8A6-4926F70472F1
P2860
The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The TGFβ-miR200-MIG6 pathway o ...... resistance to EGFR inhibitors
@en
type
label
The TGFβ-miR200-MIG6 pathway o ...... resistance to EGFR inhibitors
@en
prefLabel
The TGFβ-miR200-MIG6 pathway o ...... resistance to EGFR inhibitors
@en
P2093
P2860
P1433
P1476
The TGFβ-miR200-MIG6 pathway o ...... resistance to EGFR inhibitors
@en
P2093
Christina Michailidi
David Sidransky
Evgeny Izumchenko
Luciane Kagohara
Rajani Ravi
Shizhang Ling
Xiaofei Chang
P2860
P304
P356
10.1158/0008-5472.CAN-14-0110
P407
P577
2014-05-15T00:00:00Z